From:  Hypophosphatasia: current concepts in diagnosis and management of a rare metabolic disorder

 Laboratory assessment across clinical forms of hypophosphatasia treated with asfotase alfa.

TestPerinatal/InfantileChildhood and adult
ALPBaseline, 3, 6, 12 months and then every 6 monthsBaseline, 2 weeks, 3, 6, 12 months and then annually
Plasma PLP, calcium, phosphate, urine PEABaseline, 1, 3, 6, 12 months and then annuallyBaseline, 3 months and then annually
25OHDBaseline, 1, 3, 6, 12 months and then annually once normal levels are reachedBaseline, 3, 6, 12 months and then annually once normal levels are reached
PTHBaseline and periodically based on calcium metabolismBaseline and periodically based on calcium metabolism
Routine blood tests (CBC, liver function, electrolytes)Baseline, 3, 6, 9, 12 months and then annuallyBaseline, 6 months and then annually
Renal panel (creatinine, BUN)Baseline and every 3 monthsBaseline, 6 months and then annually
Anti-asfotase alfa antibodies (IgG)As clinically indicated and availableAs clinically indicated and available

The table is based on the references [5, 52, 89]. 25OHD: 25-hydroxyvitamin D; ALP: alkaline phosphatase; BUN: blood urea nitrogen; CBC: complete blood count; PEA: phosphoethanolamine; PLP: pyridoxal-5-phosphate; PTH: parathyroid hormone.